Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin L Avila

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Neurotoxicology|November 15, 2011
Myelin structure is unaltered in chemotherapy-induced peripheral neuropathyAlessandra Gilardini, Robin L Avila, Norberto Oggioni, et al.
Neurology and Therapy|March 26, 2023
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data AnalysisJai Perumal, Roumen Balabanov, Laura Balcer, et al.
Neurology and Therapy|February 15, 2023
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta TherapyAliya Jaber, Meera Patel, Andrew Sylvester, et al.
Journal of Neuropathology and Experimental Neurology|October 29, 2005
Structure and stability of internodal myelin in mouse models of hereditary neuropathyRobin L Avila, Hideyo Inouye, Rena C Baek, et al.
Free Radical Biology & Medicine|March 25, 2015
Plasmalogen phospholipids protect internodal myelin from oxidative damageAdrienne M Luoma, Fonghsu Kuo, Ozgur Cakici, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 13, 2023
Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumabMark Gudesblatt, Myassar Zarif, Barbara Bumstead, et al.
CNS Drugs|September 6, 2022
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.
Multiple Sclerosis and Related Disorders|April 21, 2021
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosisAnthony T Reder, Nancy Arndt, Cortnee Roman, et al.
CNS Drugs|February 13, 2023
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.
Biophysical Journal|August 19, 2007
Cytoplasmic domain of zebrafish myelin protein zero: adhesive role depends on beta-conformationXiaoYang Luo, Hideyo Inouye, Abby A R Gross, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Neurotoxicology|November 15, 2011
Myelin structure is unaltered in chemotherapy-induced peripheral neuropathyAlessandra Gilardini, Robin L Avila, Norberto Oggioni, et al.
Neurology and Therapy|March 26, 2023
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data AnalysisJai Perumal, Roumen Balabanov, Laura Balcer, et al.
Neurology and Therapy|February 15, 2023
COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta TherapyAliya Jaber, Meera Patel, Andrew Sylvester, et al.
Journal of Neuropathology and Experimental Neurology|October 29, 2005
Structure and stability of internodal myelin in mouse models of hereditary neuropathyRobin L Avila, Hideyo Inouye, Rena C Baek, et al.
Free Radical Biology & Medicine|March 25, 2015
Plasmalogen phospholipids protect internodal myelin from oxidative damageAdrienne M Luoma, Fonghsu Kuo, Ozgur Cakici, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 13, 2023
Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumabMark Gudesblatt, Myassar Zarif, Barbara Bumstead, et al.
CNS Drugs|September 6, 2022
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.
Multiple Sclerosis and Related Disorders|April 21, 2021
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosisAnthony T Reder, Nancy Arndt, Cortnee Roman, et al.
CNS Drugs|February 13, 2023
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.
Biophysical Journal|August 19, 2007
Cytoplasmic domain of zebrafish myelin protein zero: adhesive role depends on beta-conformationXiaoYang Luo, Hideyo Inouye, Abby A R Gross, et al.
Pageof 4